ArticleScientific reports2019
Broad and Efficient Control of Klebsiella Pathogens by Peptidoglycan-Degrading and Pore-Forming Bacteriocins Klebicins.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Bacterial weaponry and the ecological factors of competitive success.Essays in biochemistry · 2026Review
- Antibiotic development and a path to access in India.Nature communications · 2026Article
- Current Status and Future Challenges in the Use of Bacteriocins to Modulate Ruminant Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Innovations in process engineering approaches for enhanced bacteriocin production.Journal of industrial microbiology & biotechnology · 2026Review
- Telomere bacteriophages are widespread and equip their bacterial hosts with potent interbacterial weapons.Science advances · 2025Article
- Pharmaceutical properties of novel 3-((diisopropylamino)methyl)-5-(4-((4-(dimethylamino) benzylidene) imino) phenyl)-1,3,4-oxadiazole-2(3 H)-thione.Scientific reports · 2025Article
- Bacteriocin KvarM versus conventional antibiotics: comparative effectiveness in treatingFrontiers in cellular and infection microbiology · 2025Article
- Quantitative and qualitative analysis of bioaerosols emissions from the domestic eastern wastewater treatment plant, Alexandria, Egypt.Scientific reports · 2024Article
- Quantitative Analysis of the Inactivation Process of Internalized Bacteria in Dictyostelium Cells.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Biosynthetic gene cluster signature profiles of pathogenic Gram-negative bacteria isolated from Egyptian clinical settings.Microbiology spectrum · 2023Article
- Flow cytometric detection of vancomycin-resistant Enterococcus faecium in urine using fluorescently labelled enterocin K1.Scientific reports · 2023Article
- Prodigiosin-ProducingFoods (Basel, Switzerland) · 2023Article
- Pairing Colicins B and E5 with Bdellovibrio bacteriovorus To Eradicate Carbapenem- and Colistin-Resistant Strains of Escherichia coli.Microbiology spectrum · 2023Article
- The "Cins" of Our Fathers: Rejuvenated Interest in Colicins to Combat Drug Resistance.Journal of microbiology (Seoul, Korea) · 2023Review
- The Role of Antimicrobial Peptides as Antimicrobial and Antibiofilm Agents in Tackling the Silent Pandemic of Antimicrobial Resistance.Molecules (Basel, Switzerland) · 2022Review
- Reduction of gastrointestinal tract colonization by Klebsiella quasipneumoniae using antimicrobial protein KvarIa.Gut pathogens · 2022Article
- Chimeric bacteriocin S5-PmnH engineered by domain swapping efficiently controls Pseudomonas aeruginosa infection in murine keratitis and lung models.Scientific reports · 2022Article
- In Vitro Investigation of the Impact of Bacterial-Fungal Interaction on Carbapenem-ResistantMolecules (Basel, Switzerland) · 2022Article
- Bacterial pore-forming toxins.Microbiology (Reading, England) · 2022Article
- Phenotypic and Molecular Characterization of Commensal, Community-Acquired and NosocomialMicroorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative bacteria belonging to the genus Klebsiella are important nosocomial pathogens, readily acquiring resistance to all known antibiotics. Bacteriocins, non-antibiotic antibacterial proteins, have been earlier proposed as potential therapeutic agents for control of other Gram-negative species such as Escherichia, Pseudomonas and Salmonella. This study is the first report describing pore-forming and peptidoglycan-degrading bacteriocins klebicins from Klebsiella. We have identified, cloned, expressed in plants and characterized nine pore-forming and peptidoglycan-degrading bacteriocins from different Klebsiella species. We demonstrate that klebicins can be used for broad and efficient control of 101 of the 107 clinical isolates representing five Klebsiella species, including multi-drug resistant pathovars and pathovars resistant to carbapenem antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.